663
Participants
Start Date
January 31, 2013
Primary Completion Date
October 31, 2017
Study Completion Date
May 31, 2018
Dabigatran
NOAC
Rivaroxaban
NOAC
Apixaban
NOAC
Galilee Medical Center, Nahariya
Foothills Medical Centre, Calgary
University of Alberta-ECAT Group, Edmonton
Victoria Cardiac Arrhythmia Trials Inc., Victoria
Hamilton Health Sciences General Campus, Hamilton
Southlake Regional Health Centre, Newmarket
University of Ottawa Heart Institute, Ottawa
Rouge Valley Health System-Centenary Campus, Toronto
Humber River Hospital, Toronto
Montreal Heart Institute, Montreal
Centre Hospitalier de l'Universite de Montreal (CHUM), Hotel Dieu, Montreal
McGill University Health Centre/Montreal General Hospital, Montreal
Hopital Sacre-Coeur, Montreal
Centre Hospitalier Universitaire de Sherbrooke-Hopital Fleurimont, Sherbrooke
Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Québec
Collaborators (3)
Boehringer Ingelheim
INDUSTRY
Heart and Stroke Foundation of Canada
OTHER
Bayer
INDUSTRY
Bristol-Myers Squibb
INDUSTRY
Ottawa Heart Institute Research Corporation
OTHER